Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 2.21
DYAX's Cash to Debt is ranked lower than
71% of the 842 Companies
in the Global Biotechnology industry.

( Industry Median: 60.34 vs. DYAX: 2.21 )
Ranked among companies with meaningful Cash to Debt only.
DYAX' s 10-Year Cash to Debt Range
Min: 0.27  Med: 1.93 Max: N/A
Current: 2.21
Equity to Asset 0.48
DYAX's Equity to Asset is ranked lower than
72% of the 594 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. DYAX: 0.48 )
Ranked among companies with meaningful Equity to Asset only.
DYAX' s 10-Year Equity to Asset Range
Min: -1.26  Med: 0.36 Max: 0.82
Current: 0.48
-1.26
0.82
F-Score: 3
Z-Score: 18.89
M-Score: -1.97
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -3.25
DYAX's Operating margin (%) is ranked higher than
66% of the 657 Companies
in the Global Biotechnology industry.

( Industry Median: -71.01 vs. DYAX: -3.25 )
Ranked among companies with meaningful Operating margin (%) only.
DYAX' s 10-Year Operating margin (%) Range
Min: -389.57  Med: -102.71 Max: -1.51
Current: -3.25
-389.57
-1.51
Net-margin (%) -15.27
DYAX's Net-margin (%) is ranked higher than
61% of the 657 Companies
in the Global Biotechnology industry.

( Industry Median: -69.93 vs. DYAX: -15.27 )
Ranked among companies with meaningful Net-margin (%) only.
DYAX' s 10-Year Net-margin (%) Range
Min: -393.89  Med: -74.67 Max: -14.53
Current: -15.27
-393.89
-14.53
ROE (%) -12.95
DYAX's ROE (%) is ranked higher than
64% of the 763 Companies
in the Global Biotechnology industry.

( Industry Median: -30.92 vs. DYAX: -12.95 )
Ranked among companies with meaningful ROE (%) only.
DYAX' s 10-Year ROE (%) Range
Min: -1406.43  Med: -67.91 Max: -17.98
Current: -12.95
-1406.43
-17.98
ROA (%) -6.35
DYAX's ROA (%) is ranked higher than
68% of the 848 Companies
in the Global Biotechnology industry.

( Industry Median: -26.61 vs. DYAX: -6.35 )
Ranked among companies with meaningful ROA (%) only.
DYAX' s 10-Year ROA (%) Range
Min: -89.25  Med: -39.00 Max: -6.76
Current: -6.35
-89.25
-6.76
ROC (Joel Greenblatt) (%) -50.36
DYAX's ROC (Joel Greenblatt) (%) is ranked higher than
64% of the 819 Companies
in the Global Biotechnology industry.

( Industry Median: -356.32 vs. DYAX: -50.36 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
DYAX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1121.26  Med: -367.76 Max: -16.77
Current: -50.36
-1121.26
-16.77
Revenue Growth (3Y)(%) 7.60
DYAX's Revenue Growth (3Y)(%) is ranked higher than
60% of the 402 Companies
in the Global Biotechnology industry.

( Industry Median: 0.30 vs. DYAX: 7.60 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
DYAX' s 10-Year Revenue Growth (3Y)(%) Range
Min: -37.4  Med: -3.10 Max: 21.1
Current: 7.6
-37.4
21.1
EBITDA Growth (3Y)(%) -100.00
DYAX's EBITDA Growth (3Y)(%) is ranked lower than
99% of the 427 Companies
in the Global Biotechnology industry.

( Industry Median: -3.90 vs. DYAX: -100.00 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
DYAX' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -100  Med: -11.20 Max: 10.4
Current: -100
-100
10.4
EPS Growth (3Y)(%) -36.40
DYAX's EPS Growth (3Y)(%) is ranked lower than
84% of the 413 Companies
in the Global Biotechnology industry.

( Industry Median: -7.40 vs. DYAX: -36.40 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
DYAX' s 10-Year EPS Growth (3Y)(%) Range
Min: -37.4  Med: -8.60 Max: 11.9
Current: -36.4
-37.4
11.9
» DYAX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

DYAX Guru Trades in Q2 2014

Joel Greenblatt 46,505 sh (New)
Steven Cohen 44,100 sh (unchged)
Paul Tudor Jones Sold Out
Louis Moore Bacon Sold Out
PRIMECAP Management 11,129,830 sh (-5.74%)
Chuck Royce 380,200 sh (-21.71%)
Jim Simons 469,186 sh (-36.84%)
» More
Q3 2014

DYAX Guru Trades in Q3 2014

Paul Tudor Jones 17,323 sh (New)
Steven Cohen 56,500 sh (+28.12%)
Jim Simons Sold Out
PRIMECAP Management 10,884,960 sh (-2.20%)
Joel Greenblatt 44,152 sh (-5.06%)
Chuck Royce 244,900 sh (-35.59%)
» More
Q4 2014

DYAX Guru Trades in Q4 2014

Paul Tudor Jones 25,023 sh (+44.45%)
Joel Greenblatt 52,618 sh (+19.17%)
Steven Cohen Sold Out
PRIMECAP Management 10,869,860 sh (-0.14%)
Chuck Royce 179,600 sh (-26.66%)
» More
Q1 2015

DYAX Guru Trades in Q1 2015

Ken Fisher 182,450 sh (New)
Joel Greenblatt Sold Out
Paul Tudor Jones Sold Out
PRIMECAP Management 10,632,860 sh (-2.18%)
Chuck Royce 162,200 sh (-9.69%)
» More
» Details

Insider Trades

Latest Guru Trades with DYAX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
Forward P/E 1666.67
DYAX's Forward P/E is ranked lower than
100% of the 158 Companies
in the Global Biotechnology industry.

( Industry Median: 23.87 vs. DYAX: 1666.67 )
Ranked among companies with meaningful Forward P/E only.
N/A
P/B 35.55
DYAX's P/B is ranked lower than
97% of the 743 Companies
in the Global Biotechnology industry.

( Industry Median: 4.68 vs. DYAX: 35.55 )
Ranked among companies with meaningful P/B only.
DYAX' s 10-Year P/B Range
Min: 2.05  Med: 8.93 Max: 74.67
Current: 35.55
2.05
74.67
P/S 41.11
DYAX's P/S is ranked lower than
75% of the 591 Companies
in the Global Biotechnology industry.

( Industry Median: 11.51 vs. DYAX: 41.11 )
Ranked among companies with meaningful P/S only.
DYAX' s 10-Year P/S Range
Min: 2.46  Med: 8.13 Max: 45.63
Current: 41.11
2.46
45.63
Current Ratio 9.97
DYAX's Current Ratio is ranked higher than
74% of the 814 Companies
in the Global Biotechnology industry.

( Industry Median: 4.38 vs. DYAX: 9.97 )
Ranked among companies with meaningful Current Ratio only.
DYAX' s 10-Year Current Ratio Range
Min: 1.34  Med: 3.67 Max: 13.3
Current: 9.97
1.34
13.3
Quick Ratio 9.75
DYAX's Quick Ratio is ranked higher than
74% of the 814 Companies
in the Global Biotechnology industry.

( Industry Median: 4.23 vs. DYAX: 9.75 )
Ranked among companies with meaningful Quick Ratio only.
DYAX' s 10-Year Quick Ratio Range
Min: 1.34  Med: 3.62 Max: 13.1
Current: 9.75
1.34
13.1
Days Inventory 145.88
DYAX's Days Inventory is ranked lower than
62% of the 402 Companies
in the Global Biotechnology industry.

( Industry Median: 116.21 vs. DYAX: 145.88 )
Ranked among companies with meaningful Days Inventory only.
DYAX' s 10-Year Days Inventory Range
Min: 124.07  Med: 469.29 Max: 821.79
Current: 145.88
124.07
821.79
Days Sales Outstanding 39.99
DYAX's Days Sales Outstanding is ranked higher than
70% of the 557 Companies
in the Global Biotechnology industry.

( Industry Median: 61.10 vs. DYAX: 39.99 )
Ranked among companies with meaningful Days Sales Outstanding only.
DYAX' s 10-Year Days Sales Outstanding Range
Min: 37.74  Med: 59.09 Max: 101.42
Current: 39.99
37.74
101.42

Valuation & Return

vs
industry
vs
history
Price/Net Cash 49.64
DYAX's Price/Net Cash is ranked lower than
90% of the 448 Companies
in the Global Biotechnology industry.

( Industry Median: 8.45 vs. DYAX: 49.64 )
Ranked among companies with meaningful Price/Net Cash only.
DYAX' s 10-Year Price/Net Cash Range
Min: 3.14  Med: 10.31 Max: 251.17
Current: 49.64
3.14
251.17
Price/Net Current Asset Value 39.27
DYAX's Price/Net Current Asset Value is ranked lower than
90% of the 533 Companies
in the Global Biotechnology industry.

( Industry Median: 7.60 vs. DYAX: 39.27 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
DYAX' s 10-Year Price/Net Current Asset Value Range
Min: 2.56  Med: 7.99 Max: 62.79
Current: 39.27
2.56
62.79
Price/Tangible Book 35.55
DYAX's Price/Tangible Book is ranked lower than
95% of the 683 Companies
in the Global Biotechnology industry.

( Industry Median: 5.78 vs. DYAX: 35.55 )
Ranked among companies with meaningful Price/Tangible Book only.
DYAX' s 10-Year Price/Tangible Book Range
Min: 1.05  Med: 5.83 Max: 72
Current: 35.55
1.05
72
Price/Median PS Value 5.06
DYAX's Price/Median PS Value is ranked lower than
91% of the 539 Companies
in the Global Biotechnology industry.

( Industry Median: 1.17 vs. DYAX: 5.06 )
Ranked among companies with meaningful Price/Median PS Value only.
DYAX' s 10-Year Price/Median PS Value Range
Min: 0.14  Med: 0.89 Max: 4.08
Current: 5.06
0.14
4.08
Earnings Yield (Greenblatt) (%) -0.10
DYAX's Earnings Yield (Greenblatt) (%) is ranked higher than
73% of the 816 Companies
in the Global Biotechnology industry.

( Industry Median: -5.50 vs. DYAX: -0.10 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
DYAX' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: -2.1  Med: 0.00 Max: 0
Current: -0.1
-2.1
0

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:DY8.Germany,
Dyax Corp was incorporated in the state of Delaware in the year 1989, and merged with Protein Engineering Corporation in 1995. It is a biopharmaceutical company focused on Hereditary Angioedema and Other Plasma-Kallikrein-Mediated Disorders and Licensing and Funded Research Portfolio. The Company develops and commercializes treatments for hereditary angioedema and to identify other disorders that are mediated by plasma kallikrein. It is engaged in identifying and developing treatments for patients who experience PKM angioedema. Plasma kallikrein, an enzyme found in blood, produces bradykinin, a protein that causes blood vessels to enlarge or dilate, which can cause swelling known as angioedema. Excess plasma kallikrein activity plays a role in HAE and could potentially play a role in a number of inflammatory diseases, including Crohn's disease, psoriasis, rheumatoid arthritis, and various mast cell disorders. It also develops KALBITOR for the treatment of acute attacks of HAE. KALBITOR is currently distributed through a limited network of wholesale, hospital and specialty pharmacy arrangements. Its portfolio of product candidates being developed by licensees using its phage display technology. For KALBITOR as a treatment for HAE, its competitors include: Manufacturers of corticosteroids. Other competitors for the treatment of HAE are companies that are developing small molecule plasma kallikrein inhibitors. The preclinical study and clinical testing, manufacture, labeling, storage, record keeping, advertising, promotion, export, and marketing, among other things, of its products and product candidates, including KALBITOR and those of its licensees, are subject to extensive regulation by governmental authorities in the United States and other countries.
» More Articles for DYAX

Headlines

Articles On GuruFocus.com
Voltari Corp. (VLTC) Under Carl Icahn Umbrella, Dyax Corp. (DYAX) Potential Angioedema Preventive Tr Apr 01 2015 
Weekly CFO Buys Highlight: DYAX, IBI, FARM, TAP, DBM Mar 19 2011 
Dyax Corp. (DYAX) CEO Gustav Christensen buys 10,000 Shares Mar 15 2011 
Dyax Corp. (DYAX) CEO Gustav Christensen buys 10,000 Shares Mar 15 2011 
Dyax Corp. Reports Operating Results (10-K) Mar 02 2011 
Dyax Corp. Reports Operating Results (10-Q) Nov 02 2010 
Dyax Corp. (DYAX) CEO Gustav Christensen buys 5,000 Shares Sep 15 2010 
Dyax Corp. (DYAX) CFO George V Migausky buys 12,000 Shares Aug 25 2010 
Weekly CFO Buys Highlight: Apollo Investment Corp., Dyax Corp., Heska Corp., Vaughan Foods Inc., Wir Jun 05 2010 
Weekly CFO Buy Highlights: F.N.B. Corp, Great Wolf Resorts Inc, Dyax Corp, Transcat Inc, Cal Dive In Jun 20 2009 

More From Other Websites
Edited Transcript of DYAX presentation 1-Jun-15 7:00pm GMT Jun 27 2015
5 Biotech Stocks to Trade for Gains Jun 23 2015
Shire Watches Dyax Threat to $630,000 Orphan Drug Jun 10 2015
Dyax Corp. Presents Phase 1b DX-2930 Data at the 2015 European Academy of Allergy and Clinical... Jun 08 2015
Dyax Corp. Presents Phase 1b DX-2930 Data at the 2015 European Academy of Allergy and Clinical... Jun 08 2015
Dyax Corp. to Participate in the Jefferies 2015 Global Healthcare Conference May 27 2015
Dyax Corp. to Participate in the Jefferies 2015 Global Healthcare Conference May 27 2015
Dyax and the U.S. Hereditary Angioedema Association (HAEA) Launch the HAE Hope® Essay Contest on... May 15 2015
Dyax and the U.S. Hereditary Angioedema Association (HAEA) Launch the HAE Hope® Essay Contest on... May 15 2015
DYAX CORP Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to a... May 14 2015
Dyax Corp. Appoints Dr. Abbie Celniker to Board of Directors May 12 2015
Dyax Corp. Appoints Dr. Abbie Celniker to Board of Directors May 12 2015
Oppenheimer Downgrades Dyax May 11 2015
Dyax downgraded by Oppenheimer May 11 2015
10-Q for Dyax Corp. May 04 2015
Dyax Corp. to Participate in Upcoming Investor Conferences Apr 30 2015
Dyax Corp. to Participate in Upcoming Investor Conferences Apr 30 2015
DYAX CORP Files SEC form 10-Q, Quarterly Report Apr 30 2015
Dyax reports 1Q loss Apr 29 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK